secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001159036-23-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q2: revenue $221M, GAAP EPS $0.56, Non-GAAP $0.74; raises FY EPS guidance to $2.65-$2.75
--------------------------------------------------------------------------------

- Revenue $221.0M, +45% YoY; GAAP diluted EPS $0.56 vs $0.16 YoY; non-GAAP diluted EPS $0.74 vs $0.53.
- Royalty revenue record $111.7M (+31% YoY), driven by subcutaneous DARZALEX.
- Raised 2023 non-GAAP diluted EPS guidance to $2.65-$2.75 from $2.50-$2.65; revenue guidance $825-$845M.
- FDA approval of VYVGART Hytrulo (argenx) for gMG triggered $33M milestones and royalties.
- Positive Phase 3 data from Roche's SC ocrelizumab and argenx's CIDP trial support pipeline growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000047/0001159036-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000047/halo-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer